The New York Entrepreneur

BioNTech’s stock slides 3.4% after earnings fall short of estimates amid shrinking COVID-vaccine sales

Read Time:8 Second

The company said it has started commercializing variant-adapted COVID vaccines for the coming season, and is also building on development efforts for other drug candidates.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post FreshPet’s stock rallies after sales beat, raised outlook
Next post The Sahm Rule, carry trades and recession fear are more than the market can bear